Navigation Links
Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
Date:6/30/2008

PITTSBURGH, June 30 /PRNewswire/ -- Cellumen, Inc., the Cellular Systems Biology Company, announced today the initiation of a research collaboration with the National Center for Toxicology Research (NCTR), a research center of the Food and Drug Administration (FDA). Under the agreement, Cellumen will use its proprietary CellCiphr(R) toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds including both failed and marketed drugs for the NCTR. The NCTR will incorporate the knowledge generated by Cellumen to develop a liver toxicity knowledge base. Cellumen will use the profiling data and compound safety data from the collaboration to further develop the diversity in the CellCiphr database and the types of cell panels, as well as to advance the classifier informatics tools.

"Failure to predict human toxicity among drug candidates early in the discovery/development process is a leading challenge for the pharmaceutical industry," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "Patients demand and deserve safe and effective drugs, while pharmaceutical companies are increasingly challenged to profitably meet that demand. Cellumen's vision is working toward the goal of replacing animal testing with a human in vitro system in order to facilitate the development of safer, more effective drugs," added Dr. Taylor.

By applying CellCiphr toxicity profiling early in the discovery and lead optimization phases, drug companies will accurately identify compounds with high human toxic liabilities. Actions can be taken to either de-prioritize high-risk compounds, or remove high-risk compounds from a lead series that ultimately would prove to be toxic. Cellumen is at the forefront of drug safety profiling services to aid in predicting drug toxicity early in the discovery/development process.

About Cellumen:

Cellumen is the leading innovator in cellular systems biology (CSB(TM)) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's CSB solutions are driving "Discovery Toxicology" by addressing the full complexity of disease and safety. Leading global organizations such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, NIH and top pharmaceutical companies partner with Cellumen.

About CellCiphr(R):

CellCiphr is the only cell-based assay solution combining tissue-specific cells, multiplexed functional biomarkers, advanced classifiers, and a compound reference library in order to allow drug developers to accurately identify drug candidates that have high efficacy and low toxicity. CellCiphr is capable of analyzing greater than 10 functional biomarkers per assay that are used as sentinels for analysis of mechanism of action and toxicity of new compounds applied to both rodent and human cells.


'/>"/>
SOURCE Cellumen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
2. ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
5. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
6. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
7. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
10. NIH collaborates with EPA to improve the safety testing of chemicals
11. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2016)... Switzerland , May 18, 2016 ... GONAL-f® 2.0 prefilled pen following approval by EMA, the ... a leading science and technology company, the new pen ... bring an increased level of confidence to patients during ... new GONAL-f® prefilled pen easier to handle with a ...
(Date:5/17/2016)... ... May 17, 2016 , ... PATH ... they will collaborate to bring a feeding cup to market based on a ... the Craniofacial Center at Seattle Children’s Hospital, thereby ensuring an innovative feeding option ...
(Date:5/17/2016)... ... , ... A new study on mesothelioma trends in Sweden indicates that there ... Mesothelioma has just posted an article on the new research. Click here to ... kidney cancer seem to be more susceptible to mesothelioma, the researchers still aren’t sure ...
(Date:5/17/2016)... ... , ... New tests that go beyond the standard PSA test for detecting ... the patient and doctor want and need to know in individualizing treatment to get ... annual meeting in San Diego, involve using blood, urine and tissue samples with the ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
Breaking Biology News(10 mins):